loading
전일 마감가:
$101.08
열려 있는:
$100.77
하루 거래량:
1.99M
Relative Volume:
0.89
시가총액:
$19.65B
수익:
$4.58B
순이익/손실:
$870.87M
주가수익비율:
22.75
EPS:
4.3988
순현금흐름:
$945.58M
1주 성능:
-1.88%
1개월 성능:
+1.17%
6개월 성능:
+29.04%
1년 성능:
+35.65%
1일 변동 폭
Value
$99.28
$101.25
1주일 범위
Value
$98.85
$105.06
52주 변동 폭
Value
$53.56
$112.29

인사이트 코퍼레이션 Stock (INCY) Company Profile

Name
명칭
Incyte Corp
Name
전화
(302) 498-6700
Name
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Name
직원
2,617
Name
트위터
@Incyte
Name
다음 수익 날짜
2025-02-10
Name
최신 SEC 제출 서류
Name
INCY's Discussions on Twitter

INCY을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
INCY
Incyte Corp
100.07 19.84B 4.58B 870.87M 945.58M 4.3988
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.90 120.69B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
741.45 78.77B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
840.50 52.46B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
338.06 45.82B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
340.38 38.73B 4.98B 69.59M 525.67M 0.5197

인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2026-01-20 다운그레이드 Wells Fargo Overweight → Equal Weight
2025-12-08 업그레이드 Mizuho Neutral → Outperform
2025-11-03 업그레이드 Guggenheim Neutral → Buy
2025-10-08 다운그레이드 Oppenheimer Outperform → Perform
2025-08-06 업그레이드 Wells Fargo Equal Weight → Overweight
2025-08-01 개시 Barclays Overweight
2025-06-16 업그레이드 Stifel Hold → Buy
2025-03-18 다운그레이드 Guggenheim Buy → Neutral
2025-03-18 다운그레이드 William Blair Outperform → Mkt Perform
2024-12-17 개시 UBS Neutral
2024-10-29 업그레이드 BofA Securities Neutral → Buy
2024-10-01 개시 Wolfe Research Outperform
2024-09-18 다운그레이드 Truist Buy → Hold
2024-07-02 다운그레이드 BMO Capital Markets Market Perform → Underperform
2024-05-23 개시 Deutsche Bank Hold
2024-04-23 개시 Cantor Fitzgerald Neutral
2024-02-23 개시 Jefferies Buy
2024-02-14 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2023-12-13 업그레이드 Leerink Partners Market Perform → Outperform
2023-12-04 업그레이드 Guggenheim Neutral → Buy
2023-11-21 다운그레이드 Goldman Buy → Neutral
2023-07-25 개시 Citigroup Buy
2023-05-04 다운그레이드 BofA Securities Buy → Neutral
2023-04-10 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2023-03-24 업그레이드 SVB Securities Underperform → Market Perform
2023-01-31 개시 Piper Sandler Overweight
2022-08-03 다운그레이드 Evercore ISI Outperform → In-line
2022-08-03 다운그레이드 Guggenheim Buy → Neutral
2022-07-28 개시 Wells Fargo Equal Weight
2022-02-09 다운그레이드 SVB Leerink Mkt Perform → Underperform
2022-01-18 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2021-11-19 개시 BMO Capital Markets Market Perform
2021-07-20 업그레이드 The Benchmark Company Hold → Buy
2021-02-10 다운그레이드 SVB Leerink Mkt Perform → Underperform
2021-01-07 개시 Truist Buy
2021-01-04 업그레이드 Guggenheim Neutral → Buy
2020-06-16 개시 The Benchmark Company Hold
2020-05-06 다운그레이드 JP Morgan Overweight → Neutral
2020-04-29 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2020-04-01 업그레이드 Morgan Stanley Equal-Weight → Overweight
2020-03-24 재개 William Blair Outperform
2020-03-13 업그레이드 BofA/Merrill Neutral → Buy
2020-02-04 재개 BofA/Merrill Neutral
2020-01-03 재확인 BMO Capital Markets Market Perform
2020-01-03 다운그레이드 Mizuho Buy → Neutral
2020-01-02 다운그레이드 Guggenheim Buy → Neutral
2019-10-03 개시 Mizuho Buy
2019-09-12 개시 BMO Capital Markets Market Perform
2019-09-05 업그레이드 JMP Securities Mkt Perform → Mkt Outperform
2019-09-05 재개 Morgan Stanley Equal-Weight
2019-09-05 업그레이드 Oppenheimer Perform → Outperform
2019-05-21 개시 Credit Suisse Neutral
2019-05-03 다운그레이드 Barclays Overweight → Equal Weight
2019-04-11 개시 Stifel Hold
2019-04-03 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2019-01-24 업그레이드 William Blair Mkt Perform → Outperform
모두보기

인사이트 코퍼레이션 주식(INCY)의 최신 뉴스

pulisher
04:21 AM

Value Investing Opportunity: Incyte Corp. (NASDAQ:INCY) Presents a Compelling Case - Chartmill

04:21 AM
pulisher
Jan 30, 2026

Incyte (INCY) Gains EMA Panel Support for Expanded Use of Zynyz - GuruFocus

Jan 30, 2026
pulisher
Jan 30, 2026

Incyte (INCY) Gains European Recommendation for Zynyz Therapy - GuruFocus

Jan 30, 2026
pulisher
Jan 30, 2026

Incyte gets positive CHMP opinion for anal cancer drug Zynyz - StreetInsider

Jan 30, 2026
pulisher
Jan 30, 2026

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) - Yahoo Finance

Jan 30, 2026
pulisher
Jan 27, 2026

Undercovered Dozen: Incyte, Annaly Capital, ImmunityBio And More - Seeking Alpha

Jan 27, 2026
pulisher
Jan 27, 2026

Incyte to Report Fourth Quarter and Year-End 2025 Financial Results - Business Wire

Jan 27, 2026
pulisher
Jan 26, 2026

INCY Stock Price and Chart — NASDAQ:INCY - TradingView

Jan 26, 2026
pulisher
Jan 26, 2026

Here's Why Incyte (INCY) is a Strong Momentum Stock - Yahoo Finance

Jan 26, 2026
pulisher
Jan 26, 2026

Incyte Corporation $INCY Stock Position Lowered by Mitsubishi UFJ Trust & Banking Corp - MarketBeat

Jan 26, 2026
pulisher
Jan 23, 2026

Why Incyte (INCY) is a Top Value Stock for the Long-Term - Yahoo Finance

Jan 23, 2026
pulisher
Jan 23, 2026

Incyte Corporation $INCY Stock Position Raised by Massachusetts Financial Services Co. MA - MarketBeat

Jan 23, 2026
pulisher
Jan 23, 2026

Incyte Corporation (NASDAQ:INCY) Nasdaq Top 100 Research Depth - Kalkine Media

Jan 23, 2026
pulisher
Jan 22, 2026

Engaging In Insider Activity, Patrick Mayes At Incyte Exercises Options Worth $0 - Benzinga

Jan 22, 2026
pulisher
Jan 22, 2026

Thomas Tray Decides To Exercise Options At Incyte Worth $0 - Benzinga

Jan 22, 2026
pulisher
Jan 22, 2026

Engaging In Insider Activity, Matteo Trotta At Incyte Exercises Options Worth $0 - Benzinga

Jan 22, 2026
pulisher
Jan 22, 2026

Breaking Update: PABLO CAGNONI Engages In Options Exercise At Incyte Realizing $0 - Benzinga

Jan 22, 2026
pulisher
Jan 22, 2026

What Investors Should Know Before Buying Incyte Stock (NASDAQ:INCY) - Seeking Alpha

Jan 22, 2026
pulisher
Jan 22, 2026

Incyte Corp. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains - 富途牛牛

Jan 22, 2026
pulisher
Jan 21, 2026

Reassessing Incyte (INCY) Valuation After Wells Fargo’s Neutral Downgrade - Yahoo Finance

Jan 21, 2026
pulisher
Jan 21, 2026

Wells Fargo & Company Downgrades Incyte (NASDAQ:INCY) to Hold - MarketBeat

Jan 21, 2026
pulisher
Jan 21, 2026

Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi - MSN

Jan 21, 2026
pulisher
Jan 20, 2026

Incyte (INCY) Faces Downgrade and Adjusted Price Target by Wells Fargo - GuruFocus

Jan 20, 2026
pulisher
Jan 20, 2026

Incyte (INCY) Faces Downgrade with Revised Price Target by Wells Fargo | INCY Stock News - GuruFocus

Jan 20, 2026
pulisher
Jan 20, 2026

IBM To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Jan 20, 2026
pulisher
Jan 20, 2026

Wells Fargo downgrades Incyte stock to Equal Weight as upgrade thesis plays out - Investing.com

Jan 20, 2026
pulisher
Jan 16, 2026

New Incyte Drug Combo Shows Power Against Deadly Lymphoma - mychesco.com

Jan 16, 2026
pulisher
Jan 15, 2026

EC approves label expansion of INCY's lymphoma drug Minjuvi - MSN

Jan 15, 2026
pulisher
Jan 14, 2026

Why Incyte (INCY) Stock Is Trading Up Today - Finviz

Jan 14, 2026
pulisher
Jan 14, 2026

Is Incyte (INCY) Still Attractively Priced After Its Strong 1 Year Share Price Gain? - Yahoo Finance

Jan 14, 2026
pulisher
Jan 13, 2026

Incyte (INCY) Receives Updated Buy Rating from TD Cowen | INCY S - GuruFocus

Jan 13, 2026
pulisher
Jan 13, 2026

Incyte (NASDAQ:INCY) Given New $128.00 Price Target at TD Cowen - MarketBeat

Jan 13, 2026
pulisher
Jan 13, 2026

Palmetto Grain Brokerage - Palmetto Grain Brokerage

Jan 13, 2026
pulisher
Jan 13, 2026

Earnings Preview: What To Expect From Incyte's Report - Barchart.com

Jan 13, 2026
pulisher
Jan 13, 2026

GRIMES & Co WEALTH MANAGEMENT LLC Sells 16,883 Shares of Incyte Corporation $INCY - MarketBeat

Jan 13, 2026
pulisher
Jan 13, 2026

Analysts Offer Insights on Healthcare Companies: Incyte (INCY), SI-Bone (SIBN) and Guardant Health (GH) - The Globe and Mail

Jan 13, 2026
pulisher
Jan 12, 2026

Lobbying Update: $70,000 of INCYTE CORPORATION lobbying was just disclosed - Quiver Quantitative

Jan 12, 2026
pulisher
Jan 12, 2026

Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report? - Finviz

Jan 12, 2026
pulisher
Jan 12, 2026

Incyte Corporation (INCY) Stock Analysis: Strong Revenue Growth and Strategic Developments in the Biotech Sector - DirectorsTalk Interviews

Jan 12, 2026
pulisher
Jan 12, 2026

Incyte Corp. stock underperforms Monday when compared to competitors - MSN

Jan 12, 2026
pulisher
Jan 12, 2026

ImmunityBio, Xencor Drugs Win E.U. Nods - Los Angeles Business Journal

Jan 12, 2026
pulisher
Jan 10, 2026

INCY's phase III Monjuvi study meets key goals in first-line lymphoma - MSN

Jan 10, 2026
pulisher
Jan 10, 2026

What margin trends mean for Incyte Corporation stockOil Prices & High Return Trade Guides - Улправда

Jan 10, 2026
pulisher
Jan 10, 2026

Incyte Corporation $INCY Stock Holdings Increased by Cerity Partners LLC - MarketBeat

Jan 10, 2026
pulisher
Jan 10, 2026

Will Incyte Corporation (ICY) stock beat value stocks2025 Analyst Calls & Smart Investment Allocation Tips - ulpravda.ru

Jan 10, 2026
pulisher
Jan 09, 2026

Incyte Corporation Stock Live Price, Chart, Analysis, News & Forecast – Buy, Sell & Trade US Equities Today - livemint.com

Jan 09, 2026
pulisher
Jan 09, 2026

Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Jan 09, 2026
pulisher
Jan 09, 2026

Incyte jumps amid takeover speculation - MSN

Jan 09, 2026
pulisher
Jan 09, 2026

Bull of the Day: Eli Lilly (LLY) - Finviz

Jan 09, 2026
pulisher
Jan 09, 2026

This Biotech Stock Eyes Fresh Entry With 522% Earnings Growth Seen - Investor's Business Daily

Jan 09, 2026
pulisher
Jan 09, 2026

Can Incyte Corporation stock reach $100 price targetExit Point & Scalable Portfolio Growth Methods - ulpravda.ru

Jan 09, 2026

인사이트 코퍼레이션 (INCY) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$32.63
price down icon 2.16%
$96.95
price down icon 1.27%
$113.75
price down icon 2.59%
$156.87
price down icon 0.60%
biotechnology ONC
$340.38
price down icon 2.75%
자본화:     |  볼륨(24시간):